Home/Filings/4/0001899977-25-000004
4//SEC Filing

Schneyer Mark C. 4

Accession 0001899977-25-000004

CIK 0001070494other

Filed

Sep 15, 8:00 PM ET

Accepted

Sep 16, 6:00 PM ET

Size

6.9 KB

Accession

0001899977-25-000004

Insider Transaction Report

Form 4
Period: 2025-09-12
Schneyer Mark C.
EVP, CHIEF FINANCIAL OFFICER
Transactions
  • Award

    Common Stock

    2025-09-12+6,81546,945 total
  • Sale

    Common Stock

    2025-09-15$23.65/sh3,498$82,72843,447 total
Footnotes (2)
  • [F1]Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on May 1, 2023 at incremental 25% of target. Together with the vesting on August 16, 2024, the performance stock units have vested at 75% of target.
  • [F2]The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

Issuer

ACADIA PHARMACEUTICALS INC

CIK 0001070494

Entity typeother

Related Parties

1
  • filerCIK 0001899977

Filing Metadata

Form type
4
Filed
Sep 15, 8:00 PM ET
Accepted
Sep 16, 6:00 PM ET
Size
6.9 KB